farrerol has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, R; Li, J; Li, Q; Liang, T; Liu, E; Shi, S | 1 |
| Du, J; Fu, S; Gao, X; He, D; Hu, G; Huang, B; Li, Y; Meng, T; Ran, X; Zeng, Y; Zhang, Y | 1 |
2 other study(ies) available for farrerol and Disease Models, Animal
| Article | Year |
|---|---|
Farrerol maintains the contractile phenotype of VSMCs via inactivating the extracellular signal-regulated protein kinase 1/2 and p38 mitogen-activated protein kinase signaling.
Topics: Animals; Aorta; Cells, Cultured; Chromones; Disease Models, Animal; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle Contraction; Muscle, Smooth, Vascular; Neointima; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Phytochemicals; Rats; Rats, Sprague-Dawley; Signal Transduction; Vascular System Injuries | 2020 |
Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-κB signaling pathways.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chromones; Cytokines; Disease Models, Animal; Dopaminergic Neurons; Lipopolysaccharides; Microglia; Neuroprotective Agents; NF-kappa B; Parkinsonian Disorders; Proto-Oncogene Proteins c-akt; Rats, Wistar; Signal Transduction | 2019 |